

Cameroon has successfully stopped mass drug administration (MDA) for lymphatic filariasis in the country following the likely interruption of transmission of the causative parasite in all 142 endemic districts as of FY22 (October 2021 – September 2022).

The National program has validated the onchocerciasis national strategic plan (2020-2024). The plan defines the strategic priorities and the mechanisms necessary to achieving interruption of transmission by 2025 in all the endemic foci.
Standard Disease-Specific Indicators as of FY21
FY21 is October 2020 through September 2021

of ever-endemic districts have stopped MDA as of FY21
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))*
* MDA has stopped for LF in all districts in Cameroon except one
of ever-endemic districts in post-surveillance phase as of FY21
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY21 among those who were ever at risk

of ever-endemic districts have stopped MDA as of FY21
(i.e. have passed stop MDA survey, TIS (Trachoma Impact Survey))
of ever-endemic districts in post-MDA surveillance phase as of FY21
(i.e. have passed surveillance survey, TSS (Trachoma Surveillance Survey))
of persons no longer at risk as of FY21 among those who were ever at risk

of ever endemic districts have been treated at least once as of FY21
(in cases where a country has more treated districts reported than, ever endemic, the adjusted percent is 100%)

of ever endemic districts have been treated at least once as of FY21
